newsfilter
← Latest News
Business Wire·

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos' Phase I/II trial Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine,